International Journal of Cardiology
Volume 152, Issue 1 , Pages 43-48 , 6 October 2011

First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: Possible relationship to the “Japanese paradox”

  • Diana A. Gorog

      Affiliations

    • Imperial College, London, UK
    • Cardiology Department, East and North Hertfordshire NHS Trust, UK
    • Corresponding Author InformationCorresponding author. Imperial College, London, UK. Tel.: +44 207 034 8934; fax: +44 207 034 8935.
    • ,
  • Junichiro Yamamoto

      Affiliations

    • Laboratory of Physiology, Kobe Gakuin University, Kobe, Japan
    • ,
  • Smriti Saraf

      Affiliations

    • Cardiology Department, East and North Hertfordshire NHS Trust, UK
    • ,
  • Hiromitsu Ishii

      Affiliations

    • Ishii Hospital, Akashi, Japan
    • ,
  • Yoshinobu Ijiri

      Affiliations

    • Department of Nutrition Management, Faculty of Health Science, Hyogo University, Kakogawa, Japan
    • ,
  • Hideo Ikarugi

      Affiliations

    • Laboratory of Health and Sport Sciences, University of Hyogo, Kobe, Japan
    • ,
  • David M. Wellsted

      Affiliations

    • Health Research and Development Support Unit, University of Hertfordshire, UK
    • ,
  • Mari Mori

      Affiliations

    • Mukogawa Women's University Institute for World Health Development, Nishinomiya, Japan
    • ,
  • Yukio Yamori

      Affiliations

    • Mukogawa Women's University Institute for World Health Development, Nishinomiya, Japan

Received 1 September 2009 ,Revised 5 June 2010 ,Accepted 2 July 2010.

References 

  1. Sekikawa A, Horiuchi BY, Edmundowicz D, et al. A “natural experiment” in cardiovascular epidemiology in the early 21st century. Heart. 2003 March;89(3):255–257
  2. van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med. 2000 January 6;342(1):1–8
  3. Okayama A, Ueshima H, Marmot M, Elliott P, Choudhury SR, Kita Y. Generational and regional differences in trends of mortality from ischemic heart disease in Japan from 1969 to 1992. Am J Epidemiol. 2001 June 15;153(12):1191–1198
  4. Yoshida M, Kita Y, Nakamura Y, et al. Incidence of acute myocardial infarction in Takashima, Shiga, Japan. Circ J. 2005 April;69(4):404–408
  5. Kitamura A, Sato S, Kiyama M, et al. Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka Study. J Am Coll Cardiol. 2008 July 1;52(1):71–79
  6. Robertson TL, Kato H, Rhoads GG, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol. 1977 February;39(2):239–243
  7. Marmot MG, Syme SL, Kagan A, Kato H, Cohen JB, Belsky J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol. 1975 December;102(6):514–525
  8. Takeya Y, Popper JS, Shimizu Y, Kato H, Rhoads GG, Kagan A. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: incidence of stroke in Japan and Hawaii. Stroke. 1984 January;15(1):15–23
  9. Kita T. Coronary heart disease risk in Japan — an East/West divide?. Eur Heart J Suppl. 2004;6(suppl_A):A8–112004 March 1
  10. Egusa G, Yamane K. Lifestyle, serum lipids and coronary artery disease: comparison of Japan with the United States. J Atheroscler Thromb. 2004;11(6):304–312
  11. Sekikawa A, Ueshima H, Kadowaki T, et al. Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-world war II birth cohort. Am J Epidemiol. 2007 March 15;165(6):617–624
  12. Khoo KL, Tan H, Liew YM, Deslypere JP, Janus E. Lipids and coronary heart disease in Asia. Atherosclerosis. 2003 July;169(1):1–10
  13. Yarnell J, McCrum E, Rumley A, et al. Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study. Eur Heart J. 2005 February 2;26(4):332–342
  14. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, c-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998 May 13;279(18):1477–1482
  15. Lowe GDO, Danesh J, Lewington S, et al. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2004 February 1;25(3):252–259
  16. Whincup PH, Danesh J, Walker M, et al. von Willebrand factor and coronary heart disease. Prospective study and meta-analysis. Eur Heart J. 2002 November 2;23(22):1764–1770
  17. Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008 March 18;117(11):1449–1459
  18. Danesh J, Collins R, Peto R, Lowe GDO. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J. 2000 April 1;21(7):515–520
  19. Koenig W, Sund M, Lowe GD, et al. Geographical variations in plasma viscosity and relation to coronary event rates. Lancet. 1994 September 10;344(8924):711–714
  20. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986 September 6;2(8506):533–537
  21. Iso H, Folsom AR, Wu KK, et al. Hemostatic variables in Japanese and Caucasian men. Tissue plasminogen activator, antithrombin III, and protein C and their relations to coronary risk factors. Am J Epidemiol. 1990 July;132(1):41–46
  22. Iso H, Folsom AR, Sato S, et al. Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler Thromb. 1993 June;13(6):783–790
  23. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995 March 9;332(10):635–641
  24. Scarabin PY, Arveiler D, Amouyel P, et al. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. Atherosclerosis. 2003 January;166(1):103–109
  25. Yano K, Kodama K, Shimizu Y, et al. Plasma fibrinogen and its correlates in elderly Japanese Men living in Japan and Hawaii. J Clin Epidemiol. 1999 December;52(12):1201–1206
  26. Swan HJ. Acute myocardial infarction: a failure of timely, spontaneous thrombolysis. J Am Coll Cardiol. 1989 May;13(6):1435–1437
  27. Hamsten A, de FU, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987 July 4;2(8549):3–9
  28. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000 January;31(1):26–32
  29. Kovacs IB, Gorog DA, Yamamoto J. Enhanced spontaneous thrombolysis: a new therapeutic challenge. J Thromb Thrombolysis. 2006 June;21(3):221–227
  30. Wiman B, Hamsten A. Correlations between fibrinolytic function and acute myocardial infarction. Am J Cardiol. 1990 November 6;66(16):54G–56G
  31. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991 February 2;12(2):157–161
  32. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993 May 8;341(8854):1165–1168
  33. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood. 1990 September 1;76(5):930–937
  34. Sinkovic A, Pogacar V. Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by troponin T and plasminogen-activator–inhibitor-1 (PAI-1). Thromb Res. 2004;114(4):251–257
  35. Yamamoto J, Yamashita T, Ikarugi H, et al. Gorog Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis. 2003 January;14(1):31–39
  36. Gorog DA, Sweeny JM, Fuster V. Antiplatelet drug ‘resistance’. Part 2: laboratory resistance to antiplatelet drugs — fact or artifact?. Nat Rev Cardiol. 2009;6:365–373
  37. Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets. 2009 February;20(1):7–11
  38. Kambayashi J, Shinoki N, Nakamura T, et al. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res. 1996 January 1;81(1):85–90
  39. Lepantalo A, Beer JH, Siljander P, Syrjala M, Lassila R. Variability in platelet responses to collagen — comparison between whole blood perfusions, traditional platelet function tests and PFA-100. Thromb Res. 2001 July 15;103(2):123–133
  40. Michelson AD, Linden MD, Furman MI, et al. Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. J Thromb Haemost. 2007 January;5(1):75–81
  41. Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: definition of a thrombotic shear rate threshold. J Am Coll Cardiol. 1994 October;24(4):1091–1097
  42. Saraf S, Wellsted D, Sharma S, Gorog DA. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy. Thromb Res. 2009;124(4):447–451
  43. Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol. 2010;55(19):2107–2115
  44. Barrabés JA, Galian L. Endogenous thrombolysis: a hidden player in acute coronary syndromes?. J Am Coll Cardiol. 2010;11(55):2116–2117
  45. Hachinski V. Stroke in Japanese. Stroke. 2006 May 1;37(5):1143
  46. Kitamura A, Nakagawa Y, Sato M, et al. Proportions of stroke subtypes among men and women >=40 years of age in an urban Japanese City in 1992, 1997, and 2002. Stroke. 2006 June 1;37(6):1374–1378
  47. Kubo M, Kiyohara Y, Kato I, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama Study. Stroke. 2003 October 1;34(10):2349–2354
  48. Iso H, Folsom AR, Koike KA, et al. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: correlates in nonsmoking Japanese and Caucasian men and women. Thromb Haemost. 1993 September 1;70(3):475–480
  49. Takamiya T, Kadowaki T, Zaky WR, et al. The determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40–49. Diabetes Res Clin Pract. 2006 May;72(2):176–182
  50. Gorog DA. Prognostic Value of Plasma Fibrinolysis Activation Markers in Cardiovascular Disease. J Am Coll Cardiol. 2010;55:2701–2709
  51. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(10)00529-2

doi: 10.1016/j.ijcard.2010.07.002

International Journal of Cardiology
Volume 152, Issue 1 , Pages 43-48 , 6 October 2011

Article Tools

* Image Usage & Resolution